ArticleTransboundary and emerging diseases2025
Novel Strain-Based Triple Inactivated Vaccine Confers Rapid Neutralizing Immunity to Feline Multisystemic Pathogens With Two-Dose Regimen.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in Feline Panleukopenia Virus Vaccines: Immunological Mechanisms, Current Challenges, and Future Perspectives.Viruses · 2026Review
- Review
- Establishment of a loop-mediated isothermal amplification-lateral flow dipstick assay for the point-of-care testing of feline herpesvirus-1.Frontiers in veterinary science · 2026Article
- Evaluating triple inactivated vaccine-induced immunity from a large-scale study in feline population.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid global increase in companion animal populations and the rising risks of zoonotic diseases necessitate urgent advancements in veterinary vaccines. In China, over 100 million domestic cats are vulnerable to three deadly pathogens: feline calicivirus (FCV), feline herpesvirus type 1 (FHV-1), and feline panleukopenia virus (FPV). Existing trivalent vaccines face challenges, such as antigenic mismatches, supply chain inefficiencies, and delayed regional adaptability, highlighting the need for localized solutions. In response, we present Meowonder, the first fully indigenous triple feline vaccine developed using contemporary Chinese isolates of FCV, FHV-1, and FPV. Through inactivation and formulation with a proprietary adjuvant, Meowonder has achieved superior safety and immunogenicity and has been approved for the Chinese market. In controlled trials, two doses of Meowonder resulted in robust neutralizing antibody responses, surpassing commercial vaccines in preventing clinical symptoms such as oral ulcers, respiratory distress, and tissue damage after exposure. Clinical studies involving 1818 cats confirmed the efficacy of the two-dose regimen across various ages and regions, with no significant benefit from a third dose. Significantly, Meowonder reduced viral shedding and maintained healthy leukocyte levels following FPV exposure, which is crucial for environments with multiple cats. Histopathological analyses indicated complete protection against FCV-associated mucosal necrosis, FPV-induced intestinal lesions, and FHV-1-driven respiratory damage. By aligning vaccine antigens with circulating strains, Meowonder addresses regional virological diversity and sets a new standard for feline immunization. It offers a scalable solution to enhance the health of companion animals in China and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.